Published online before print March 3, 2003, doi: 10.1161/01.CIR.0000055319.94801.FC
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2003;107:1424.)
© 2003 American Heart Association, Inc.
Basic Science Reports |
Downregulation of Cytoskeletal Muscle LIM Protein by Nitric Oxide
Impact on Cardiac Myocyte Hypertrophy
From the Departments of Cardiology and Angiology (J.H., T. Kempf, A.H., H.D., K.C.W.) and Molecular and Cellular Physiology (T. Kraft), Hannover Medical School, Hannover, Germany; the Institute of Pathophysiology (H.M.) and the Department of Cardiothoracic Surgery (R.J.S.), University of Halle-Wittenberg, Halle-Wittenberg, Germany; the Friedrich-Miescher Institute (P.C.), Basel, Switzerland; and the Institute of Clinical Biochemistry and Pathobiochemistry (S.M.L.), University of Würzburg, Würzburg, Germany.
Correspondence to Priv-Doz Dr med Kai C. Wollert, Abteilung Kardiologie und Angiologie, Medizinische Hochschule Hannover, Carl-Neuberg Straße 1, 30625 Hannover, Germany. E-mail wollert.kai{at}mh-hannover.de
 |
Abstract |
|---|
 Top Abstract IntroductionMethodsResultsDiscussionReferences |
|---|
Background— In chronic heart failure, myocardial expression of the inducible isoform of nitric oxide (NO) synthase (NOS2) is enhanced, leading to a sustained production of NO. We postulated that NO modulates expression of genes in cardiac myocytes that may be functionally important in the context of cardiac hypertrophy and failure.
Methods and Results— As revealed by cDNA expression array analyses, the NO donor SNAP, which has been shown previously to inhibit agonist-induced cardiac myocyte hypertrophy, downregulates expression of the cytoskeleton-associated muscle LIM protein (MLP) in endothelin-1 (ET-1)–stimulated neonatal rat cardiac myocytes. Northern blotting and immunoblotting experiments confirmed this finding and established that SNAP negatively controls MLP mRNA (-49%, P<0.01) and protein (-52%, P<0.01) abundance in ET-1–treated cardiomyocytes via cGMP-dependent protein kinase and superoxide/peroxynitrite-dependent signaling pathways. Treatment of cardiac myocytes with IL-1ß and IFN-
downregulated MLP expression levels via induction of NOS2. Moreover, expression levels of NOS2 and MLP were inversely correlated in the failing human heart, indicating that NOS2 may regulate MLP abundance in vitro and in vivo. Antisense oligonucleotides were used to explore the functional consequences of reduced MLP expression levels in cardiac myocytes. Like SNAP, antisense downregulation of MLP protein expression (-52%, P<0.01) blunted the increases in protein synthesis, cell size, and sarcomere organization in response to ET-1 stimulation. Conversely, overexpression of MLP augmented cell size and sarcomere organization in cardiac myocytes.
Conclusions— NO negatively controls MLP expression in cardiac myocytes. Because MLP is necessary and sufficient for hypertrophy and sarcomere assembly, MLP downregulation may restrain hypertrophic growth in pathophysiological situations with increased cardiac NO production.
Key Words: nitric oxide • cytoskeleton • myocytes • hypertrophy
|
Introduction |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
In chronic heart failure and other disease states associated with inflammation and cytokine activation, myocardial expression of the inducible isoform of nitric oxide (NO) synthase (NOS2) is enhanced, leading to a sustained production of NO.1–4 NO has been shown to attenuate cardiac myocyte hypertrophy,5–8 to promote cardiac myocyte apoptosis,9,10 and to modulate cardiac myocyte contractile function.2,11 Studies in NOS2-deficient and NOS2-overexpressing mice indicate that upregulation of NOS2 is detrimental and may increase mortality in heart failure.12–14 The effects of NO in various cell types and tissues are mediated, in part, via changes in gene expression,15 raising the possibility that transcriptional effects of NO may play a role in cardiac hypertrophy and failure as well. Little is known, however, regarding the effects of NO on the gene expression profile in cardiac myocytes. In the present study , we have performed cDNA expression array analyses to identify genes that are regulated by NO in cardiac myocytes and that may be functionally important in the context of cardiac hypertrophy and failure. Using this approach , we have identified muscle LIM protein (MLP) as one gene that is downregulated by NO in cardiac myocytes. Muscle LIM protein is a member of the LIM-only class of the LIM domain protein family that is highly expressed at the Z disk in striated muscle cells.16,17 Homozygous deletion of individual LIM domain protein genes in mice results in distinct forms of cardiomyopathy and heart failure , indicating that LIM domain proteins play critical roles in supporting cardiac structure and function.18–20 It was recently shown that MLP expression levels are decreased in the failing human heart , suggesting that MLP may play a role in acquired forms of heart failure as well.21 Exploring the functional consequences of reduced MLP expression , our study reveals that MLP is necessary and sufficient for hypertrophic growth and sarcomere organization in cardiac myocytes and that downregulation of MLP contributes significantly to the antihypertrophic effects of NO.
See p 1348
|
Methods |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Materials
Endothelin-1 (ET-1), superoxide dismutase (SOD), the guanylyl cyclase inhibitor 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one (ODQ), and the NOS2 inhibitor 2-amino-5,6-dihydro-6-methyl-4H-1,3-thiazine (AMT) were purchased from Sigma; the NO donor S-nitroso-N-acetyl-D,L-penicillamine (SNAP) and the SOD mimetic Mn(III)tetrakis(4-benzoic acid)porphyrin (MnTBAP) from Calbiochem; tetramethylammonium-peroxynitrite (peroxynitrite) from Alexis; the cGMP analog 8-para-chlorophenylthio-cGMP (8-pCPT-cGMP) from Biolog; and interleukin (IL)-1ß and interferon (IFN)-
from R&D Systems.
Cardiac Myocyte Culture
Ventricular cardiac myocytes were isolated from 1- to 3-day-old Sprague-Dawley rats (Control Animal Facility, Hannover Medical School) by Percoll gradient. Cells were plated overnight in DMEM/medium 199 (4:1) supplemented with 10% horse serum, 5% FCS, glutamine, and antibiotics. The next morning, cardiac myocytes were switched to DMEM/medium 199 supplemented with only glutamine and antibiotics (maintenance medium).7
cDNA Expression Array Analysis
Total RNA was isolated by use of the Trizol reagent (Life Technologies) and treated with DNase I (1 U/µL) to remove residual genomic DNA. cDNA probes were synthesized in the presence of [
-32P]dATP (Amersham) by use of SuperScript II reverse transcriptase (Life Technologies), purified by column chromatography, and denatured in NaOH. Probes were hybridized for 18 hours at 68°C to Atlas rat 1.2 nylon arrays (Clontech) containing cDNA sequences from 1176 rat genes. The arrays were then washed under stringent conditions, exposed to a phosphorimaging screen, and analyzed with AtlasImage 2.0 software (Clontech).
Northern Blot and Reverse Transcription–Polymerase Chain Reaction
MLP mRNA expression was determined by Northern blot. An MLP cDNA probe was generated by polymerase chain reaction cloning (forward primer nt 25 to 45, reverse primer nt 701 to 726),16 subcloned into pCR2.1 (Invitrogen) and confirmed by DNA sequencing. NOS2 and ß-actin mRNA expression levels were determined by semiquantitative reverse transcription–polymerase chain reaction.22
Immunoblotting
MLP protein expression was determined by immunoblotting using a polyclonal antibody directed against the C-terminal peptide of rat MLP (GGLTHQVEKKE).16 This antibody recognizes rat and human MLP.16,21 A monoclonal antibody from Transduction Laboratories was used to quantify NOS2 expression. Equal loading was confirmed by Ponceau red staining and immunoblotting with a monoclonal antibody directed against -actinin (Sigma).
Human Myocardial Tissue
Left ventricular tissue samples were obtained from patients with end-stage heart failure undergoing heart transplantation (n=31; mean age, 54±2 years; mean left ventricular ejection fraction, 23±2%). All patients were in NYHA functional class III or IV. Tissue samples were frozen in liquid nitrogen no later than 2 hours after explantation.
Adenoviral Infection of Cardiac Myocytes
A replication-deficient adenovirus containing the cDNA of human cGMP-dependent protein kinase type I (PKG I) was used to overexpress PKG I in cardiac myocytes (Ad.PKG I).7,23 Control cells were infected with a replication-deficient adenovirus encoding a point-mutated, catalytically inactive form of human PKG I (Ad.PKG I-K405A).7,24 Infection with Ad.PKG I augments PKG activity 12-fold compared with noninfected or Ad.PKG I-K405A–infected cardiac myocytes.7
Antisense Oligonucleotides
Following previously published guidelines for the design of antisense experiments,25 a set of 5 antisense oligonucleotides (18-mers) directed against the ATG translation start site of rat MLP were synthesized to selectively decrease MLP expression levels in cardiomyocytes. Three phosphorothioate linkages were introduced at the 3' and 5' termini of each oligonucleotide. Cardiac myocytes were transfected for 4 hours with antisense oligonucleotides using the cationic reagent Lipofectamine (Invitrogen). Each oligonucleotide was initially screened for its ability to decrease MLP expression levels. Antisense oligonucleotide 4 (AS4, nt 41 to 58) downregulated MLP protein expression most potently and was used in subsequent experiments. Antisense oligonucleotides AS1, AS3, and AS5 were less effective. Antisense oligonucleotide 2 (AS2, nt 25 to 42) and a scrambled oligonucleotide corresponding to AS4 (SCR, GACCCTACCAGCTCTCGC) did not suppress MLP levels and served as negative controls. Control experiments using FITC-labeled AS4 and SCR oligonucleotides revealed that virtually all cardiomyocytes were successfully transfected with our protocol (not shown).
Assessment of Cardiac Myocyte Hypertrophy and Survival
Cell size was determined by planimetry.7 Immunostaining was performed as previously described,26 with a monoclonal antibody against -actinin, from Sigma. Sarcomere organization was analyzed by a blinded observer (T. Kempf) by confocal laser microscopy in cardiac myocytes immunostained for -actinin. A semiquantitative grading system was used: grade 1, <10% of cell area with sarcomere organization; grade 2, 10 to 50% of cell area with sarcomere organization; grade 3, 50% to 90% of cell area with sarcomere organization; and grade 4, >90% of cell area with sarcomere organization. [3H]leucine incorporation was measured as an index of total protein synthesis.7 Atrial natriuretic peptide (ANP) mRNA expression was assessed by Northern blot.26 Cell viability was determined by trypan blue exclusion, and the formation of histone-associated DNA fragments, a marker of apoptotic cell death, was quantified by cell death detection ELISAPLUS (Roche).7
Plasmid Constructs and Transfection
Cardiac myocytes were Lipofectamine-transfected for 4 hours with cytomegalovirus promoter–based eukaryotic expression plasmids encoding ß-galactosidase or MLP.18 Transfected cells were identified by histochemical staining for ß-galactosidase or by immunostaining for ß-galactosidase (polyclonal antibody from Invitrogen). ANP promoter activity was determined in cells transfected with a luciferase reporter plasmid driven by 3003 bp of the rat ANP gene 5' flanking region.26
Statistical Analysis
Data are presented as mean±SEM. Differences between groups were analyzed by 1-way ANOVA and Student-Newman-Keuls post hoc test. Linear regression analysis was performed to test for a correlation between 2 variables. A 2-tailed probability value of P<0.05 was considered to indicate statistical significance.
|
Results |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
cDNA Expression Array Analyses Reveal Downregulation of MLP by NO in Cardiac Myocytes
Radiolabeled cDNA probes were generated from cardiac myocytes stimulated for 24 hours with the prohypertrophic polypeptide ET-1 (100 nmol/L)27 or ET-1 and the NO donor SNAP (250 µmol/L). At this concentration, SNAP promotes antihypertrophic but not proapoptotic effects in our experimental system.7,8 The cDNA probes were hybridized to nylon arrays containing cDNA fragments from 1176 rat genes. Altogether, 10 genes were identified that were induced or downregulated
1.7-fold by SNAP (Table). Expression of MLP was downregulated by SNAP in ET-1–treated cardiac myocytes. Subsequent experiments were performed to explore the molecular mechanisms and functional consequences of this observation.
|
MLP Is Downregulated by NO and Induced by ET-1 in Cardiac Myocytes
Northern blotting and immunoblotting experiments confirmed the array data and established that MLP mRNA and protein abundance is downregulated by SNAP in ET-1–treated cardiomyocytes (Figure 1, A through D). A similar trend was observed in the absence of ET-1. Dose-response experiments revealed that stimulation with 50 µmol/L SNAP is required for MLP downregulation (not shown). Notably, ET-1 stimulation was associated with a significant increase in MLP abundance (Figure 1, A through D). Taken together, induction (by ET-1) and suppression (by NO) of cardiac myocyte hypertrophy are associated with augmented and reduced MLP levels, respectively.
|
NO Downregulates MLP by cGMP-Dependent and Superoxide/Peroxynitrite-Dependent Mechanisms
In general, NO can alter gene expression via cGMP-dependent and cGMP-independent signaling pathways. PKG I has been identified as a critical downstream target of cGMP in this regard.28 One important cGMP-independent pathway involves the reaction of NO with superoxide to form peroxynitrite.29 The suppressive effects of SNAP on MLP abundance in ET-1–treated cardiomyocytes were partially reduced by the superoxide scavenger SOD (Figure 2A) and by the SOD mimetic MnTBAP (not shown), indicating that superoxide is involved in the inhibitory effects of NO. Treatment of cardiac myocytes with SOD alone (without SNAP) had no significant effect on MLP abundance, indicating that superoxide itself does not control MLP expression (Figure 2A). Peroxynitrite, when added directly to the cells, significantly suppressed MLP expression levels in ET-1–stimulated cardiomyocytes (Figure 2B). The data presented in Figure 2, A and B, support the concept that NO suppresses MLP expression, in part, by reacting with superoxide and promoting peroxynitrite formation. As shown in Figure 2C, NO-mediated downregulation of MLP in ET-1–treated cells was also partially blunted by the guanylyl cyclase inhibitor ODQ, indicating that cGMP-dependent mechanisms also contribute to the inhibitory effects of NO. The suppressive effects of NO were completely reversed by combined treatment with ODQ and SOD (Figure 2C). Taken together, suppression of MLP abundance by NO in ET-1–treated cardiac myocytes is mediated via cGMP-dependent (Figure 2C) and superoxide/peroxynitrite-dependent (Figure 2, A and B) pathways.
|
cGMP-Dependent Downregulation of MLP Is Mediated by PKG I
MLP expression levels in ET-1–treated cardiomyocytes were suppressed by the cell-permeable cGMP analogue 8-pCPT-cGMP (Figure 2D), supporting the concept that MLP abundance is regulated by cGMP-dependent mechanisms. Treatment with SOD did not blunt the inhibitory effects of 8-pCPT-cGMP (not shown). We have previously demonstrated that 8-pCPT-cGMP activates PKG I in cardiac myocytes,7 suggesting that the effects of cGMP on MLP expression are mediated by PKG I. To directly examine the role of PKG I as a regulator of MLP abundance, cardiomyocytes were infected with adenoviral vectors encoding wild-type or catalytically inactive PKG I. Adenoviral expression of wild-type but not inactive PKG I augmented the inhibitory effects of SNAP (not shown) and 8-pCPT-cGMP (Figure 2D) on MLP levels in ET-1–treated cardiomyocytes, indicating that PKG I acts as a downstream mediator for NO and cGMP.
Cytokine-Induced NOS2 Downregulates MLP Expression Levels in Cardiac Myocytes
Consistent with a previous report,10 stimulation with IL-1ß and IFN- induced NOS2 expression in cardiac myocytes under basal conditions and during ET-1 stimulation (Figure 3A). At the same time, IL-1ß/IFN- significantly suppressed MLP expression levels in ET-1–treated cells (Figure 3B). A similar trend was observed in the absence of ET-1. Coincubation of cytokine-stimulated cardiac myocytes with the NOS2 inhibitor AMT reversed the inhibitory effects on MLP abundance in ET-1–treated cells, indicating that IL-1ß/IFN- suppressed MLP levels via NOS2 (Figure 3B).
|
NOS2 and MLP Expression Levels Are Inversely Correlated in the Failing Human Heart
To start exploring whether NOS2 regulates MLP abundance in the failing human heart, NOS2 and MLP protein expression levels were determined in left ventricular myocardium from patients with end-stage heart failure caused by ischemic or dilated cardiomyopathy. As shown in Figure 4, NOS2 and MLP protein levels were inversely correlated in the failing human heart (n=31, r=-0.43, P<0.01). An inverse correlation was also seen in a separate analysis of patients with ischemic cardiomyopathy (n=14, r=-0.55, P<0.05). A similar trend was observed in patients with dilated cardiomyopathy (n=17, r=-0.41, P=0.1).
|
Antisense Downregulation of MLP Suppresses Cardiac Myocyte Hypertrophy
MLP antisense oligonucleotides were used to investigate the functional consequences of MLP downregulation in cardiac myocytes. As shown in Figure 5, A and B, transfection of cardiac myocytes with AS4 but not AS2 or a scrambled oligonucleotide suppressed MLP protein abundance in ET-1–treated cardiomyocytes by 52%, which was comparable to the degree of downregulation induced by SNAP (Figure 1). Antisense downregulation of MLP significantly suppressed ET-1–induced cardiac myocyte hypertrophy, as shown by a reduction of [3H]leucine incorporation (Figure 5C), cell size (Figure 5D), and sarcomere organization (Figure 5,E and F). ET-1 induction of ANP mRNA expression was not suppressed by antisense downregulation of MLP (not shown). Antisense downregulation of MLP in cardiomyocytes did not reduce cell viability (trypan blue exclusion) and did not promote formation of histone-associated DNA fragments, a marker of apoptotic cell death (not shown).
|
MLP Promotes Increases in Cell Size and Sarcomere Organization
Overexpression of MLP from a cytomegalovirus promoter–based expression plasmid promoted significant increases in cell size (Figure 6A) and sarcomere organization (Figure 6B), consistent with a direct hypertrophic effect of MLP. The growth-promoting effects of MLP were not inhibited by SNAP (Figure 6, A and B). However, overexpression of MLP reversed the inhibitory effects of SNAP on cell size in ET-1–treated cardiac myocytes (Figure 6A). Overexpression of MLP did not activate ANP transcription, as shown by cotransfection of the MLP expression plasmid with an ANP promoter–luciferase reporter plasmid (not shown).
|
|
Discussion |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Biological functions of NO are mediated in part via transcriptional effects.15,28,29 To identify NO-regulated genes that may be functionally important in the context of cardiac hypertrophy and failure, we analyzed the expression profile of 1176 genes in cardiac myocytes stimulated with the prohypertrophic polypeptide ET-1 in the presence or absence of the NO donor SNAP. Several genes were identified that were differentially regulated by NO (Table). One gene that was consistently downregulated by NO in ET-1–treated cardiac myocytes was MLP. The present study provides an in-depth analysis of the functional consequences of this observation.
Northern blotting and immunoblotting experiments confirmed and extended the cDNA expression array data by showing that NO downregulates MLP expression in cardiac myocytes at both the mRNA and protein levels. NO has been shown previously to inhibit cardiac myocyte hypertrophy, at least in part, via cGMP and its activation of PKG I.7,8 Similarly, our data imply a cGMP/PKG I-dependent pathway in the negative regulation of MLP abundance in cardiac myocytes. In addition, reaction of NO with superoxide leading to peroxynitrite formation appears to contribute to the inhibitory effects of NO on MLP expression levels. Combined blockade of both pathways with a guanylyl cyclase inhibitor and SOD completely prevented the inhibitory effects of NO on MLP expression, indicating that both pathways are operating in concert.
MLP is a member of the LIM-only class of the LIM domain protein family, which is highly expressed in striated muscle cells, in which it induces myogenic differentiation.16,17 In cardiac myocytes, MLP is localized at the Z disk, where it anchors the sarcomere to the sarcolemma by interacting with -actinin and ß-spectrin.18,30 As shown in our study, MLP expression levels are dynamically regulated in cardiac myocytes and play a critical role in the modulation of hypertrophic growth responses. Stimulation of cardiac myocyte hypertrophy by ET-1 was associated with an increase in MLP expression levels. Importantly, this increase in MLP abundance was required for some aspects of the hypertrophic response to ET-1, because a specific antisense oligonucleotide that blunted the upregulation of MLP significantly suppressed ET-1 induced increases in protein synthesis, cell size, and sarcomere organization. By contrast, upregulation by ET-1 of the embryonic marker gene ANP appeared to be mediated via MLP-independent mechanisms. Remarkably, the effects of antisense downregulation of MLP on these distinct hypertrophy markers are virtually identical to the antihypertrophic effects mediated by SNAP.7,8 Therefore, MLP downregulation may be one important mechanism contributing to the antihypertrophic effects of NO in cardiac myocytes. In line with this conclusion, overexpression of MLP reversed the inhibitory effects of SNAP on cell size in ET-1–treated cardiac myocytes. Overexpression of MLP by itself promoted increases in cardiac myocyte size and sarcomere organization, indicating that enhanced expression of MLP is not only necessary (as shown in our antisense experiments) but also sufficient to induce morphological markers of cardiac myocyte hypertrophy. Interestingly, MLP overexpression did not augment ANP promoter activity, confirming that ANP is regulated by MLP-independent pathways. Like MLP, overexpression of -actinin–associated LIM protein has been shown to promote sarcomere organization in cardiac myocytes.19 The precise molecular mechanisms that couple MLP (and other LIM-domain proteins) to hypertrophy and sarcomere assembly remain to be elucidated. Conceptually, LIM domain proteins may act as scaffold proteins and may thereby facilitate sarcomere assembly and cell enlargement. Furthermore, it has been proposed that LIM domain proteins may trigger as yet unknown downstream signaling events.31 Activation of such signaling pathways may provide additional means of promoting hypertrophy.
A growing body of evidence shows that the cytoskeleton plays an important role in transmitting growth signals from the cell membrane to the nucleus.32 Mutations in cytoskeletal protein genes are the molecular basis for many inherited forms of dilated cardiomyopathy.33 How well these genetically based forms of chamber dilation reflect events in the more prevalent forms of heart failure remains an unresolved question. However, quantitative (expression levels) and qualitative (disorganization) changes within the cytoskeleton have been described in acquired forms of heart failure.34 In this context, it has been reported that MLP levels are decreased by 
50% in patients with end-stage heart failure caused by ischemic or dilated cardiomyopathy.21 In our study, protein expression levels of NOS2 and MLP were inversely correlated in the failing human heart. Although a causal relation cannot be inferred with certainty from these data, it is conceivable that NOS2-derived NO suppresses MLP abundance in the failing human heart. In support of this concept, upregulation of NOS2 by IL-1ß and IFN- suppressed MLP expression levels in cultured cardiac myocytes. It is not clear whether low MLP levels contribute to the process of heart failure progression, are an epiphenomenon, or are part of a compensatory response.35 Considering that increased MLP levels are necessary for cardiac myocyte hypertrophy, downregulation of MLP may restrain hypertrophic growth in the failing heart. Intriguingly, mice with a homozygous deletion of MLP, ie, a complete loss of MLP expression, develop ventricular dilation and failure, although the molecular mechanisms involved remain largely unknown.18,31 To further define the consequences of a partial MLP deficiency that is observed in response to NO stimulation and in the failing human heart, future studies should determine the impact of a heterozygous deletion of MLP on cardiac remodeling and hypertrophy.
In conclusion, our study reveals a link between NO and cytoskeletal alterations in cardiac myocytes that may be functionally important in the setting of cardiac hypertrophy and failure.
|
Acknowledgments |
|---|
This work was supported by grants from the Deutsche Forschungsgemeinschaft to Dr Wollert (WO 552/2-1) and Dr Lohmann (SFB 355).
Received October 29, 2002; accepted December 5, 2002.
|
References |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
1. Haywood GA, Tsao PS, von der Leyen HE, et al. Expression of inducible nitric oxide synthase in human heart failure. Circulation. 1996; 93: 1087–1094.
2. Drexler H, Kastner S, Strobel A, et al. Expression, activity and functional significance of inducible nitric oxide synthase in the failing human heart. J Am Coll Cardiol. 1998; 32: 955–963.
3. Vejlstrup NG, Bouloumie A, Boesgaard S, et al. Inducible nitric oxide synthase (iNOS) in the human heart: expression and localization in congestive heart failure. J Mol Cell Cardiol. 1998; 30: 1215–1223.[CrossRef][Medline] [Order article via Infotrieve]
4. Drexler H. Nitric oxide synthases in the failing human heart: a doubled-edged sword? Circulation. 1999; 99: 2972–2975.
5. Calderone A, Thaik CM, Takahashi N, et al. Nitric oxide, atrial natriuretic peptide, and cyclic GMP inhibit the growth-promoting effects of norepinephrine in cardiac myocytes and fibroblasts. J Clin Invest. 1998; 101: 812–818.[Medline] [Order article via Infotrieve]
6. Scherrer-Crosbie M, Ullrich R, Bloch KD, et al. Endothelial nitric oxide synthase limits left ventricular remodeling after myocardial infarction in mice. Circulation. 2001; 104: 1286–1291.
7. Wollert KC, Fiedler B, Gambaryan S, et al. Gene transfer of cGMP-dependent protein kinase I enhances the antihypertrophic effects of nitric oxide in cardiomyocytes. Hypertension. 2002; 39: 87–92.
8. Fiedler B, Lohmann SM, Smolenski A, et al. Inhibition of calcineurin-NFAT hypertrophy signaling by cGMP-dependent protein kinase type I in cardiac myocytes. Proc Natl Acad Sci U S A. 2002; 99: 11363–11368.
9. Ing DJ, Zang J, Dzau VJ, et al. Modulation of cytokine-induced cardiac myocyte apoptosis by nitric oxide, Bak, and Bcl-x. Circ Res. 1999; 84: 21–33.
10. Arstall MA, Sawyer DB, Fukazawa R, et al. Cytokine-mediated apoptosis in cardiac myocytes: the role of inducible nitric oxide synthase induction and peroxynitrite generation. Circ Res. 1999; 85: 829–840.
11. Gealekman O, Abassi Z, Rubinstein I, et al. Role of myocardial inducible nitric oxide synthase in contractile dysfunction and ß-adrenergic hyporesponsiveness in rats with experimental volume-overload heart failure. Circulation. 2002; 105: 236–243.
12. Feng Q, Lu X, Jones DL, et al. Increased inducible nitric oxide synthase expression contributes to myocardial dysfunction and higher mortality after myocardial infarction in mice. Circulation. 2001; 104: 700–704.
13. Sam F, Sawyer DB, Xie Z, et al. Mice lacking inducible nitric oxide synthase have improved left ventricular contractile function and reduced apoptotic cell death late after myocardial infarction. Circ Res. 2001; 89: 351–356.
14. Mungrue IN, Gros R, You X, et al. Cardiomyocyte overexpression of iNOS in mice results in peroxynitrite generation, heart block, and sudden death. J Clin Invest. 2002; 109: 735–743.[CrossRef][Medline] [Order article via Infotrieve]
15. Pfeilschifter J, Eberhardt W, Beck KF. Regulation of gene expression by nitric oxide. Pflugers Arch. 2001; 442: 479–486.[CrossRef][Medline] [Order article via Infotrieve]
16. Arber S, Halder G, Caroni P. Muscle LIM protein, a novel essential regulator of myogenesis, promotes myogenic differentiation. Cell. 1994; 79: 221–231.[CrossRef][Medline] [Order article via Infotrieve]
17. Arber S, Caroni P. Specificity of single LIM motifs in targeting and LIM/LIM interactions in situ. Genes Dev. 1996; 10: 289–300.
18. Arber S, Hunter JJ, Ross J Jr, et al. MLP-deficient mice exhibit a disruption of cardiac cytoarchitectural organization, dilated cardiomyopathy, and heart failure. Cell. 1997; 88: 393–403.[CrossRef][Medline] [Order article via Infotrieve]
19. Pashmforoush M, Pomies P, Peterson KL, et al. Adult mice deficient in actinin-associated LIM-domain protein reveal a developmental pathway for right ventricular cardiomyopathy. Nat Med. 2001; 7: 591–597.[CrossRef][Medline] [Order article via Infotrieve]
20. Zhou Q, Chu PH, Huang C, et al. Ablation of Cypher, a PDZ-LIM domain Z-line protein, causes a severe form of congenital myopathy. J Cell Biol. 2001; 155: 605–612.
21. Zolk O, Caroni P, Bohm M. Decreased expression of the cardiac LIM domain protein MLP in chronic human heart failure. Circulation. 2000; 101: 2674–2677.
22. Kacimi R, Long CS, Karliner JS. Chronic hypoxia modulates the interleukin-1ß–stimulated inducible nitric oxide synthase pathway in cardiac myocytes. Circulation. 1997; 96: 1937–1943.
23. Begum N, Sandu OA, Ito M, et al. Active Rho kinase (ROK-) associates with insulin receptor substrate-1 and inhibits insulin signaling in vascular smooth muscle cells. J Biol Chem. 2002; 277: 6214–6222.
24. Smolenski A, Poller W, Walter U, et al. Regulation of human endothelial cell focal adhesion sites and migration by cGMP-dependent protein kinase I. J Biol Chem. 2000; 275: 25723–25732.
25. Stein CA. The experimental use of antisense oligonucleotides: a guide for the perplexed. J Clin Invest. 2001; 108: 641–644.[CrossRef][Medline] [Order article via Infotrieve]
26. Wollert KC, Taga T, Saito M, et al. Cardiotrophin-1 activates a distinct form of cardiac muscle cell hypertrophy: assembly of sarcomeric units in series via gp130/leukemia inhibitory factor receptor-dependent pathways. J Biol Chem. 1996; 271: 9535–9545.
27. Shubeita HE, McDonough PM, Harris AN, et al. Endothelin induction of inositol phospholipid hydrolysis, sarcomere assembly, and cardiac gene expression in ventricular myocytes: a paracrine mechanism for myocardial cell hypertrophy. J Biol Chem. 1990; 265: 20555–20562.
28. Eigenthaler M, Lohmann SM, Walter U, et al. Signal transduction by cGMP-dependent protein kinases and their emerging roles in the regulation of cell adhesion and gene expression. Rev Physiol Biochem Pharmacol. 1999; 135: 173–209.[Medline] [Order article via Infotrieve]
29. Droge W. Free radicals in the physiological control of cell function. Physiol Rev. 2002; 82: 47–95.
30. Flick MJ, Konieczny SF. The muscle regulatory and structural protein MLP is a cytoskeletal binding partner of betaI-spectrin. J Cell Sci. 2000; 113: 1553–1564.[Abstract]
31. Chien KR, Olson EN. Converging pathways and principles in heart development and disease. Cell. 2002; 110: 153–162.[CrossRef][Medline] [Order article via Infotrieve]
32. Wang N, Butler JP, Ingber DE. Mechanotransduction across the cell surface and through the cytoskeleton. Science. 1993; 260: 1124–1127.
33. Seidman JG, Seidman C. The genetic basis for cardiomyopathy: from mutation identification to mechanistic paradigms. Cell. 2001; 104: 557–567.[CrossRef][Medline] [Order article via Infotrieve]
34. Hein S, Kostin S, Heling A, et al. The role of the cytoskeleton in heart failure. Cardiovasc Res. 2000; 45: 273–278.
35. Katz AM. Cytoskeletal abnormalities in the failing heart: out on a LIM? Circulation. 2000; 101: 2672–2673.
Related Article:
Circulation 2003 107: 1348-1349.
This article has been cited by other articles:
 |
|
 |
|
  V. Papalouka, D. A. Arvanitis, E. Vafiadaki, M. Mavroidis, S. A. Papadodima, C. A. Spiliopoulou, D. T. Kremastinos, E. G. Kranias, and D. Sanoudou Muscle Lim Protein Interacts with Cofilin 2 and Regulates F-Actin Dynamics in Cardiac and Skeletal Muscle Mol. Cell. Biol., November 15, 2009; 29(22): 6046 - 6058. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. S. Dhalla, H. K. Saini-Chohan, D. Rodriguez-Leyva, V. Elimban, M. R. Dent, and P. S. Tappia Subcellular remodelling may induce cardiac dysfunction in congestive heart failure Cardiovasc Res, February 15, 2009; 81(3): 429 - 438. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
U. Landmesser, K. C. Wollert, and H. Drexler Potential novel pharmacological therapies for myocardial remodelling Cardiovasc Res, February 15, 2009; 81(3): 519 - 527. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Korf-Klingebiel, T. Kempf, T. Sauer, E. Brinkmann, P. Fischer, G. P. Meyer, A. Ganser, H. Drexler, and K. C. Wollert Bone marrow cells are a rich source of growth factors and cytokines: implications for cell therapy trials after myocardial infarction Eur. Heart J., December 1, 2008; 29(23): 2851 - 2858. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. W. Donker, J. G. Maessen, F. Verheyen, F. C. Ramaekers, R. L. H. M. G. Spatjens, H. Kuijpers, C. Ramakers, P. M. H. Schiffers, M. A. Vos, H. J. G. M. Crijns, et al. Impact of acute and enduring volume overload on mechanotransduction and cytoskeletal integrity of canine left ventricular myocardium Am J Physiol Heart Circ Physiol, May 1, 2007; 292(5): H2324 - H2332. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Thai, L. Castellano, E. Juneman, H. Phan, R. Do, M. A. Gaballa, and S. Goldman Pretreatment With Angiotensin Receptor Blockade Prevents Left Ventricular Dysfunction and Blunts Left Ventricular Remodeling Associated With Acute Myocardial Infarction Circulation, October 31, 2006; 114(18): 1933 - 1939. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Fiedler, R. Feil, F. Hofmann, C. Willenbockel, H. Drexler, A. Smolenski, S. M. Lohmann, and K. C. Wollert cGMP-dependent Protein Kinase Type I Inhibits TAB1-p38 Mitogen-activated Protein Kinase Apoptosis Signaling in Cardiac Myocytes J. Biol. Chem., October 27, 2006; 281(43): 32831 - 32840. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Hilfiker-Kleiner, U. Landmesser, and H. Drexler Molecular Mechanisms in Heart Failure: Focus on Cardiac Hypertrophy, Inflammation, Angiogenesis, and Apoptosis J. Am. Coll. Cardiol., October 27, 2006; 48(9_Suppl_A): A56 - A66. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. E. Murdoch, M. Zhang, A. C. Cave, and A. M. Shah NADPH oxidase-dependent redox signalling in cardiac hypertrophy, remodelling and failure Cardiovasc Res, July 15, 2006; 71(2): 208 - 215. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. R. Wilding, C. A. Lygate, K. E. Davies, S. Neubauer, and K. Clarke MLP accumulation and remodelling in the infarcted rat heart Eur J Heart Fail, June 1, 2006; 8(4): 343 - 346. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Hataishi, A. C. Rodrigues, J. G. Morgan, F. Ichinose, G. Derumeaux, K. D. Bloch, M. H. Picard, and M. Scherrer-Crosbie Nitric oxide synthase 2 and pressure-overload-induced left ventricular remodelling in mice Exp Physiol, May 1, 2006; 91(3): 633 - 639. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Kempf, M. Eden, J. Strelau, M. Naguib, C. Willenbockel, J. Tongers, J. Heineke, D. Kotlarz, J. Xu, J. D. Molkentin, et al. The Transforming Growth Factor-{beta} Superfamily Member Growth-Differentiation Factor-15 Protects the Heart From Ischemia/Reperfusion Injury Circ. Res., February 17, 2006; 98(3): 351 - 360. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Vornanen, M. Hassinen, H. Koskinen, and A. Krasnov Steady-state effects of temperature acclimation on the transcriptome of the rainbow trout heart Am J Physiol Regulatory Integrative Comp Physiol, October 1, 2005; 289(4): R1177 - R1184. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M. Shah Divergent roles of endothelial nitric oxide synthase in cardiac hypertrophy and chamber dilatation? Cardiovasc Res, June 1, 2005; 66(3): 421 - 422. [Full Text] [PDF]
|
|
|
|
 |
|
 G. W. Booz Putting the Brakes on Cardiac Hypertrophy: Exploiting the NO-cGMP Counter-Regulatory System Hypertension, March 1, 2005; 45(3): 341 - 346. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Heineke, H. Ruetten, C. Willenbockel, S. C. Gross, M. Naguib, A. Schaefer, T. Kempf, D. Hilfiker-Kleiner, P. Caroni, T. Kraft, et al. Attenuation of cardiac remodeling after myocardial infarction by muscle LIM protein-calcineurin signaling at the sarcomeric Z-disc PNAS, February 1, 2005; 102(5): 1655 - 1660. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Fiedler and K. C Wollert Interference of antihypertrophic molecules and signaling pathways with the Ca2+-calcineurin-NFAT cascade in cardiac myocytes Cardiovasc Res, August 15, 2004; 63(3): 450 - 457. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Tongers, B. Fiedler, D. Konig, T. Kempf, G. Klein, J. Heineke, T. Kraft, S. Gambaryan, S. M Lohmann, H. Drexler, et al. Heme oxygenase-1 inhibition of MAP kinases, calcineurin/NFAT signaling, and hypertrophy in cardiac myocytes Cardiovasc Res, August 15, 2004; 63(3): 545 - 552. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H.-R. Liu, L. Tao, E. Gao, B. L Lopez, T. A Christopher, R. N Willette, E. H Ohlstein, T.-L. Yue, and X.-L. Ma Anti-apoptotic effects of rosiglitazone in hypercholesterolemic rabbits subjected to myocardial ischemia and reperfusion Cardiovasc Res, April 1, 2004; 62(1): 135 - 144. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. B. Pilz and D. E. Casteel Regulation of Gene Expression by Cyclic GMP Circ. Res., November 28, 2003; 93(11): 1034 - 1046. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Badorff and S. Dimmeler NO Balance: Regulation of the Cytoskeleton in Congestive Heart Failure by Nitric Oxide Circulation, March 18, 2003; 107(10): 1348 - 1349. [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||